RIGEL PHARMACEUTICALS INC — Director's Dealing 2017

Apr 21, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: RIGEL PHARMACEUTICALS INC (RIGL)
CIK: 0001034842
Period of Report: 2017-04-19

Reporting Person: VANCE DOLLY (EVP Corp. Affairs, G.C., Sect.)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-04-19	Employee Stock Option (Right to Buy)	$3.59	A	62500	Acquired	2024-02-27	Common Stock (62500)	Direct
2017-04-19	Employee Stock Option (Right to Buy)	$2.74	A	150000	Acquired	2026-01-26	Common Stock (150000)	Direct

Footnotes

F1: On February 27, 2014 the reporting person was granted an option to purchase 125,000 shares of common stock. The option vested based on the Compensation Committee's determination that one or more pre-established performance conditions had been achieved. As previously reported on April 4, 2016, the Compensation Committee determined that the performance condition had been achieved with respect to 62,500 shares of common stock. On April 19, 2017, the Compensation Committee determined that the performance conditions had been achieved with respect to the remaining 62,500 shares of common stock, resulting in full vesting of the option.

F2: On January 26, 2016 the reporting person was granted an option to purchase 150,000 shares of common stock. The option vested based on the Compensation Committee's determination that one or more pre-established performance conditions had been achieved. On April 19, 2017, the Compensation Committee determined that the performance conditions had been achieved, resulting in full vesting of the option.